Source: JHVEPhoto / Shutterstock.com Teva Pharmaceuticals (NYSE:TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. Francis will take over as the president and CEO of Teva Pharmaceuticals starting on Jan. 1, 2023. This will have him replacing Kåre Schultz, who will retire from those roles on…

Given the potential, tremendous benefits of Cassava’s Alzheimer’s drug for millions of patients and the high probability of the drug being approved, I believe that Cassava Sciences (NASDAQ:SAVA) stock is vastly undervalued. Source: Pavel Kapysh / Shutterstock.com Additionally, my calculations indicate that the shares could easily soar over 200x after the company’s Alzheimer’s treatment, simufilam,…

Last week was one of the strangest ones I’ve seen in a long while. The mood on Wall Street soured tangibly without any significant evidence of deterioration in price. The indices were still within a half percent of an all-time high, yet the headlines read of corrections. The commentary sounded like we had already dropped…

In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in vaccine research resumed earlier this year when Covid variants emerged. Once again, markets did not learn their lesson from…

Allegations questioning the ‘accuracy and integrity’ of data from Cassava Sciences’ (NASDAQ:SAVA) Phase-3 clinical studies for Simufilam, its Alzheimer treatment, surfaced on Aug. 25. SAVA stock got pummeled on the news. Source: Shutterstock / PopTika SAVA stock, which closed on Aug. 24 at $117.83, is down to $53.64 at the start of Aug. 31. While…

Short squeeze investing is fun. It keeps you on the edge of your seat. Is a play going to pop today, or later in the week? Is it going to pop at all? These questions make things more exciting, and they lead to a great payoff when they work out. But don’t misunderstand; long-term, studied…

After the U.S. Food and Drug Administration approved Biogen (NASDAQ:BIIB) Alzheimer’s drug, it fueled an uptrend for Cassava Sciences (NASDAQ:SAVA). But in late July, buying euphoria capitulated. SAVA stock traded as high as $146.16 before plunging. Now it’s at below $97. Source: Shutterstock Cassava stock broke below the key 50-day moving average but above the…

A decade ago, after returning to finance from 30 years covering computer technology, I got into an argument over a company called Dendreon. You’ll see why this lingering thoughts connects me to BIIB stock below. Source: PictureDesignSwiss / Shutterstock.com Dendreon had launched a treatment for prostate cancer called Provenge. It is an immunotherapy, tied to…

It’s been a tale of two cities on Wall Street revealing the haves and have-nots. Yet the triumph and despair has also reinforced the narrative of many diverse blue-chip, tech stocks seemingly caught in the middle. Let’s explore three of these stocks whose struggles on the price chart now position them for big-time gains for bullish…

India Globalization Capital (NYSE:IGC) is up monumentally today. The company appears to be taking a leap further into the world of biotech with its newest announcement. It appears IGC stock is being boosted by a patent issued to the company for its cannabis-derived Alzheimer’s treatment. Source: Shutterstock Alzheimer’s disease is a hot topic among biotech and…

If you thought Reddit stocks were nearing the end of their usefulness, think again. The slump seen across plays like AMC (NYSE:AMC) plagued the class of securities in the last few weeks, but it is looking smaller in the rearview mirror as these stocks begin to grow again. Cassava Sciences (NASDAQ:SAVA) is no different; today, SAVA stock…

FibroGen (NASDAQ:FGEN) stock is falling hard on Friday after the company received the results of a review for one of its drugs. Source: Bukhta Yurii / Shutterstock.com Those results come in the form of a vote from the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee. This group voted to not…

Moderna (NASDAQ:MRNA) stock is on the rise Friday as the company prepares to join the S&P 500. Source: Shutterstock MRNA stock is set to join the S&P 500 before trading starts on Wednesday. The reason for Moderna joining has to do with a deal between Alexion Pharmaceuticals (NASDAQ:ALXN) and AstraZeneca (NASDAQ:AZN). This will have AstraZeneca…

It looks like the recent controversy surrounding Biogen (NASDAQ:BIIB) is not dying down. In fact, bearish attitudes toward the company’s newest drug are seemingly coming back to haunt it. Now, hospitals are taking aim against the company, and BIIB stock is being sent tumbling today as a result. Source: Pavel Kapysh / Shutterstock.com On June…

It’s been a big quarter for biotech stocks. Biogen (NASDAQ:BIIB) had a major breakthrough with the approval of its Alzheimer’s vaccine aducanumab, which is sold under the brand name Aduhelm. It marks the first time an Alzheimer’s therapy has been green-lit over 20 years and targets the pathophysiology of the disease. Though there are differing…

2021 has been a year of positive returns for major U.S. stock indexes after an impressive year of gains despite volatility in 2020. The Dow Jones is up 12%, the S&P 500 is up 13% and the lagging Nasdaq Composite is still up 9% year-to-date. With ongoing chatter about inflation concerns and a potential shift…

Vertex Pharma (NASDAQ:VRTX) stock is dropping on Friday following the release of results from a Phase 2 clinical trial. Source: Shutterstock That trial was testing the effectiveness of VX-864. This is a possible treatment for patients suffering from alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype. According to the company, it saw statistical improvement from…

Copyright © 2021 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201. Home / Today’s Market / CCXI Stock: 12 Things to Know About ChemoCentryx as Shares Surge Today Retail traders have high hopes for CCXI stock By William White, InvestorPlace Writer Jun 11, 2021, 11:15 am EDT June 11, 2021…

  • 1
  • 2